<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        47-92-03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2003
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EDRONAX 4MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        REBOXETINE MESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        33.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PFIZER" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AX18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance in Edronax is reboxetine which is part of a group of medicines called antidepressants. Edronax is used in acute treatment of depressive illness / major depression as well as for maintaining the improvement of your symptoms when you have initially responded to treatment with reboxetine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Edronax</strong></p><ul><li>If you are allergic to Reboxetine or any of the other ingredients of this medicine (listed in section 6).</li></ul><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p><strong>&nbsp;</strong></p><p>Talk to your doctor or pharmacist before taking Edronax</p><ul><li><u>if you:</u>suffer from convulsions or epilepsy. Treatment with reboxetine should be stopped if seizures occur.</li><li>have any signs of urinary problems, enlarged prostate or a history of heart problems.</li><li>are taking medicines to lower your blood pressure.</li><li>have liver or kidney problems. Your doctor may need to adjust your dosage.</li><li>are taking any other medicine for depression such as MAO inhibitors, tricyclics, nefazodone, SSRIs (such as fluvoxamine) or lithium.</li><li>are taking other MAO inhibitors such as linezolid (an antibiotic) or methylene blue (see section &ldquo;Other medicines and Edronax&rdquo;).</li><li>ever had episodes of mania (overactive behaviour or thoughts).</li><li>have eye problems, such as certain kinds of glaucoma (increased pressure in the eye).</li></ul><p>&nbsp;</p><p><u>Thoughts of suicide and worsening of your depression:</u></p><p><strong>If you are depressed you can sometimes have thoughts of harming or killing yourself</strong>. These may be increased when first starting antidepressants, since these medicines all take time to work, usually about two weeks but sometimes longer.</p><p>You may be more likely to think like this:</p><p>- If you have previously had thoughts about killing or harming yourself.</p><p>- If you are a young adult. Information from clinical trials has shown an increased risk of suicidal behaviour in adults aged less than 25 years with psychiatric conditions who were treated with an antidepressant.</p><p>If you have thoughts of harming or killing yourself at any time, <strong>contact your doctor or go to a hospital straight away.</strong></p><p>&nbsp;</p><p><strong>You may find it helpful to tell a relative or close friend </strong>that you are depressed, and ask them to read this leaflet. You might ask them to tell you if they think your depression is getting worse, or if they are worried about changes in your behaviour.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Edronax should not usually be used in children and adolescents less than 18 years old. Patients under 18 have an increased risk of undesirable effects, such as suicide attempt, suicidal thoughts and hostility (mainly aggressiveness, oppositional behaviour and anger) when they are treated with this class of medicines. Nevertheless, it is possible that your doctor decides to prescribe Edronax to a patient under 18 if it is in the patient&#39;s interest. If your doctor has prescribed Edronax to a patient less than 18 years old and you want to discuss this, please contact him/her.</p><p>&nbsp;</p><p>Furthermore, if any of the symptoms listed above appear or worsen when a patient under 18 is taking Edronax, you should inform your doctor.</p><p>&nbsp;</p><p>Also, the long-term safety of Edronax in regard to growth, maturation and cognitive and behavioural development in this age group has not yet been demonstrated.</p><p>&nbsp;</p><p><strong>Other medicines and Edronax</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Edronax may affect or be affected by other medicines. These include:</p><p>&nbsp;</p><ul><li>Certain antifungals, e.g. ketoconazole</li></ul><ul><li>Certain antibiotics, e.g. erythromycin, rifampicin</li><li>Medicines called ergot derivatives used to treat migraine or Parkinson&rsquo;s disease</li><li>Certain antidepressants called MAO inhibitors, tricyclics, nefazodone, SSRIs (such as fluvoxamine) or lithium</li><li>Other MAO inhibitors such as linezolid (an antibiotic) and methylene blue (used to treat high levels of methaemoglobin in the blood)</li><li>Any potassium-losing diuretics (medicines for eliminating water), e.g thiazides</li><li>Medicines used to treat epilepsy e.g. phenobarbital, carbamazepine and phenytoin</li><li>Herbal medicines containing St. John&rsquo;s Wort <em>(Hypericum perforatum)</em></li></ul><p>&nbsp;</p><p>Your doctor will tell you whether you can take Edronax with other medicines. Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription, herbal medicines, as well as vitamins and minerals.</p><p>&nbsp;</p><p><strong>Edronax with food and drink</strong></p><p>Edronax can be taken with or without food.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy</strong></p><p>There are no adequate experiences from the use of Edronax in pregnant women. Do not take Edronax if you are pregnant, unless your doctor considers it absolutely necessary, following a careful clinical risk/benefit consideration. Tell your doctor immediately if you are pregnant or are planning to become pregnant.</p><p>&nbsp;</p><p><strong>Breast-feeding</strong></p><p>Edronax passes into the breast milk in small amounts. There is a risk of a potential effect on the baby. Therefore, you should discuss the matter with your doctor and he/she will decide whether you should stop breast-feeding or stop the therapy with Edronax.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>Caution is recommended when driving or using machines.</p><p>You should not drive or operate machinery until you know you are not affected (i.e. feel drowsy) by Edronax, and that it is safe to do so.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose in &nbsp;adults &nbsp;is 8 mg a day (one 4mg tablet twice a day). Based on how you respond to the medicine, after 3 to 4 weeks your doctor may tell you to take up to 10mg per day if necessary. The maximum daily dose should not exceed 12mg.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with poor kidney or liver function, the starting dose is 4 mg per day. This may be increased depending on the individual response.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The use of Edronax 4 mg tablets cannot be recommended for elderly patients.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Edronax should not be used in children and adolescents under 18 years.</p><p>&nbsp;</p><p>The tablets should be taken in two divided doses, one dose in the morning and one in the evening. You should swallow your tablet with a glass of water. Do not chew the tablet.</p><p>To help you remember to take Edronax, you may find it easier to take your tablets at the same time every day.</p><p>&nbsp;</p><p>&nbsp;</p><p>Like other drugs Edronax will not relieve your symptoms immediately. You should start to feel better within a few weeks.</p><p>It is important that you continue to take your tablets, even though you feel better, until your doctor advises you to stop. Please be patient, if you stop taking your tablets too early, your symptoms might come back.</p><p>&nbsp;</p><p><strong>If you take more Edronax than you should</strong></p><p>You should never take more tablets than your doctor recommends. If you take too many tablets, contact your doctor or local hospital immediately. If you take more Edronax than you should, you may experience symptoms of overdose including low blood pressure, anxiety and hypertension.</p><p>&nbsp;</p><p><strong>If you forget to take Edronax</strong></p><p>If you forget to take Edronax, take your next dose at the normal time. Do not take a double dose to make up for a forgotten tablet.</p><p>&nbsp;</p><p><strong>If you stop taking Edronax</strong></p><p>You should not stop your medicine without talking to your doctor, as your symptoms may come back.</p><p>&nbsp;</p><p>There have been a few reports of withdrawal symptoms including headache, dizziness, nervousness and nausea, (feeling sick), when patients stopped treatment with Edronax.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicinecan cause side effects, although not everybody gets them. With Edronax most side effects are mild and usually go away after the first few weeks of treatment.</p><p>&nbsp;</p><p>If any of the side effects below gets serious, or if you notice any side effects not listed in this leaflet,&nbsp; please tell your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>Very common side effects</strong> (more than one in 10 patients)</p><ul><li>Difficulties to sleep (insomnia)</li><li>Dizziness</li><li>Dry mouth</li><li>Constipation</li><li>Nausea (feeling sick)</li><li>Sweating</li></ul><p>&nbsp;</p><p><strong>Common side effects</strong> (less than one in 10 patients)</p><ul><li>Headache</li><li>Lack or loss of appetite</li><li>Agitation, anxiety</li><li>Paraesthesia (pins and needles), inability to sit or stand still, altered taste sensation</li><li>&nbsp;Lack of visual focus</li><li>Increased heart rate, palpitation (heart pounding)</li><li>Widened blood vessels, fall in blood pressure when standing up, increased blood pressure</li><li>Vomiting</li><li>Rash</li><li>Sensation of incomplete emptying or slowed emptying of the bladder, urinary infection, painful urination, inability to completely empty the bladder</li><li>Erectile dysfunction (impotence), ejaculatorypain or ejaculatory delay</li><li>Chills</li></ul><p>&nbsp;</p><p><strong>Uncommon side effects</strong> (between 1 and 10 out of 1000 patients)</p><ul><li>Dilated pupils</li><li>Spinning sensation</li></ul><p>&nbsp;</p><p><strong>Rare side effects </strong>(between 1 and 10 out of 10000 patients)</p><ul><li>Glaucoma (a condition resulting in increased pressure in the eye)</li></ul><p>&nbsp;</p><p><strong>After marketing Reboxetine, the following side effects have been reported:</strong></p><ul><li>Hyponatremia (very low levels of sodium in the blood)</li><li>Aggressive behaviour, hallucination</li><li>Suicidal ideation, Suicidal behaviour</li></ul><p>Cases of suicidal ideation and suicidal behaviours have been reported during</p><p>reboxetine therapy or early after treatment discontinuation (see section 2 &ldquo;Warnings and precautions &rdquo;)</p><ul><li>Cold extremities, Raynaud&rsquo;s phenomenon (poor blood circulation to the extremities usually in the toes and fingers but could also affect nose and ears, the skin turns pale and becomes cold and numb)</li><li>Allergic skin inflammation</li><li>Testicular pain</li><li>Irritability</li><li>Increased pressure in the eye</li></ul><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance and Drug Safety Centre ( NPC )</p><p>&middot;&nbsp;&nbsp;&nbsp; Fax: +966 11 205 7662</p><p>&middot;&nbsp;&nbsp;&nbsp; Call NPC at 00966 11 2038222, Exts: 2317-2356-2340</p><p>&middot;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Store Edronax below30&deg;C.</li><li>Keep out of reach and sight of children.</li></ul><ul><li>Shelf life : 24 months</li></ul><p>&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is reboxetine.</p><ul><li>Each tablet contains 4mg of reboxetine</li></ul><p>&nbsp;</p><p>The other ingredients are:</p><ul><li>Cellulose microcrystalline, calcium hydrogen phosphate dihydrate, crospovidone, silica colloidal hydrated and magnesium stearate.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Edronax are white, round, convex tablets with a breakline. A ‘P’ is marked on the left side of the breakline and a ‘U’ is marked on the right side. The side opposite the breakline is marked “7671”. The tablet can be divided into equal doses.

Edronax is available in 10, 20, 50, 60, 100, 120, and 180 tablets in blisters packs, 60 tablets in glass bottles, multipacks of 3x60, 5x60 and 10x60 tablets in blisters; and 3x60, 5x60 and 10x60 tablets in glass bottles. 

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder:</strong></p><p>PFIZER ITALIA S.R.L &ndash; VIA ISONZO, 71 &ndash; 04100 Latina</p><p><strong>&nbsp;</strong></p><p><strong>Manufacturer:</strong></p><p>Pfizer Italia S.r.l. - 63100 Localita Marino Del Tronto - Ascoli Piceno, Italy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	This leaflet was last revised June 2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p style="direction: rtl;">المادة الفعالة في إدروناكس هي ريبوكسيتين، وهي جزء من مجموعة من الأدوية يُطلق عليها مضادات الاكتئاب. يُستخدم إدروناكس كعلاج مكثف للأمراض الاكتئابية/الاكتئاب الشديد وأيضًا للحفاظ على مستوى تحسن الأعراض التي تعاني منها عندما تكون قد حققت استجابة مبدئية للعلاج بريبوكسيتين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;"><strong>لا تتناول إدروناكس</strong></p><ul><li style="direction: rtl;">إذا كنت مصابًا بالحساسية تجاه ريبوكسيتين أو أي من المكونات الأخرى لهذا الدواء<em> </em>(المدرجة في القسم 6).</li></ul><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>تحذيرات واحتياطات</strong></p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">تحدث إلى طبيبك أو الصيدلي قبل تناول إدروناكس</p><p style="direction: rtl;">&middot;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;إذا كنت تعاني من التشنجات أو الصرع. أوقف العلاج بريبوكسيتين في حالة حدوث نوبات.</p><ul><li style="direction: rtl;">إذا كنت تعاني من أي علامات على وجود مشكلات بولية أو تضخم البروستاتا أو إذا كان لديك تاريخ من مشكلات القلب.</li><li style="direction: rtl;">إذا كنت تتناول أدوية لخفض ضغط دمك.</li><li style="direction: rtl;">إذا كنت تعاني من مشكلات بالكبد أو الكليتين. قد يحتاج طبيبك إلى تعديل جرعتك.</li><li style="direction: rtl;">إذا كنت تتناول أي دواء آخر لعلاج الاكتئاب مثل مثبطات أكسيداز أحادي الأمين (MAO)، أو المركبات ثلاثية الحلقات، أو نيفازودون، أو مثبطات استرداد السيروتونين الانتقائية (SSRIs) (مثل فلوفوكسامين)، أو الليثيوم.</li><li style="direction: rtl;">إذا كنت تتناول مثبطات أكسيداز أحادي الأمين الأخرى مثل لينيزوليد (مضاد حيوي) أو أزرق الميثيلين (انظر قسم &quot;الأدوية الأخرى وإدروناكس&quot;).</li><li style="direction: rtl;">إذا كنت قد أصبت من قبل بنوبات هوس (نشاط مفرط في السلوك أو الأفكار).</li><li style="direction: rtl;">إذا كنت تعاني من مشكلات في العين، مثل أنواع معينة من الزرق (زيادة الضغط داخل العين).</li></ul><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><u>الأفكار الانتحارية وتدهور حالة الاكتئاب التي تعاني منها:</u></p><p style="direction: rtl;"><strong>إذا كنت تعاني من الاكتئاب، فقد تراودك في بعض الأحيان أفكار لإيذاء نفسك أو الانتحار.</strong> وقد تزيد هذه الأفكار في المراحل الأولى من تناول مضادات الاكتئاب، حيث تستغرق كل هذه الأدوية وقتًا كي يظهر مفعولها، عادةً ما يمتد لحوالي أأسبوعين ولكن أحيانًا ما تستغرق أكثر من ذلك.</p><p style="direction: rtl;">قد تزداد احتمالات أن تراودك مثل هذه الأفكار في الحالات التالية:</p><p style="direction: rtl;">- إذا كنت قد فكرت من قبل في إيذاء نفسك أو الانتحار.</p><p style="direction: rtl;">- إذا كنت بالغًا يافعًا. أظهرت المعلومات المستقاة من التجارب الإكلينيكية زيادة خطر السلوك الانتحاري بين البالغين الأصغر من 25 عامًا الذين يعانون من حالات نفسية وتم علاجهم بأحد مضادات الاكتئاب.</p><p style="direction: rtl;">إذا راودتك أفكار لإيذاء نفسك أو الانتحار في أي وقت، <strong>فقم بالاتصال بطبيبك أو توجه إلى المستشفى على الفور.</strong></p><p style="direction: rtl;"><strong>&nbsp;</strong></p><p style="direction: rtl;"><strong>قد تجد أنه من المفيد إبلاغ أحد أقربائك أو أصدقائك المقربين</strong> بأنك تعاني من الاكتئاب، واطلب منه قراءة هذه النشرة. يمكنك أن تطلب منه إبلاغك إذا كان يعتقد أن الاكتئاب الذي تعاني منه يسوء أو إذا كان قلقًا من حدوث تغيرات في سلوكك.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>الأطفال والمراهقون</strong></p><p style="direction: rtl;">ينبغي عادة عدم استخدام إدروناكس مع الأطفال والمراهقين الأصغر من 18 عامًا. يكون المرضى الأصغر من 18 عامًا أكثر عرضة لخطر الإصابة بآثار غير مرغوب فيها، مثل محاولة الانتحار والأفكار الانتحارية والعدائية (بشكل أساسي العدوانية والسلوكيات المعارضة والغضب) عند علاجهم بهذه الفئة من الأدوية. وعلى الرغم من ذلك، فقد يقرر طبيبك أن يصف إدروناكس لمريض أصغر من 18 عامًا إذا كان هذا يصب في مصلحة المريض. إذا وصف طبيبك إدروناكس لمريض أصغر من 18 عامًا وأردت مناقشة هذا الأمر، يُرجى الاتصال به.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">بالإضافة إلى ذلك، إذا ظهرت أي من الأعراض المدرجة أعلاه أو إذا تفاقمت أثناء تناول مريض أصغر من 18 عامًا لإدروناكس، ينبغي عليك إخبار طبيبك.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">كذلك لم يتم إثبات السلامة طويلة الأمد لإدروناكس فيما يخص النمو والنضوج والتطور الإدراكي والسلوكي في هذه الفئة العمرية.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>الأدوية الأخرى وإدروناكس</strong></p><p style="direction: rtl;">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">قد يؤثر إدروناكس على أدوية أخرى أو يتأثر بها. وهذه الأدوية تتضمن:</p><p style="direction: rtl;">&nbsp;</p><ul><li style="direction: rtl;">أنواع معينة من مضادات الفطريات، مثل كيتوكونازول</li></ul><ul><li style="direction: rtl;">أنواع معينة من المضادات الحيوية، مثل إريثرومايسين، ريفامبيسين</li><li style="direction: rtl;">أدوية يُطلق عليها مشتقات الإرجوت تُستخدم لعلاج الصداع النصفي أو مرض باركنسون</li><li style="direction: rtl;">نوع معين من مضادات الاكتئاب يُطلق عليه مثبطات أكسيداز أحادي الأمين، أو مضادات الاكتئاب ثلاثية الحلقات، أو نيفازودون، أو مثبطات إعادة امتصاص السيروتونين الانتقائية (مثل فلوفوكسامين)، أو الليثيوم</li><li style="direction: rtl;">مثبطات أكسيداز أحادي الأمين الأخرى مثل لينيزوليد (مضاد حيوي) وأزرق الميثيلين (يُستخدم لعلاج مستويات الميتهيموجلوبين المرتفعة في الدم)</li><li style="direction: rtl;">أي مدرات للبول تتسبب في طرد البوتاسيوم من الجسم (أدوية لإخراج الماء)، مثل الثيازيدات</li><li style="direction: rtl;">الأدوية التي تُستخدم لعلاج الصرع، مثل، فينوباربيتال وكاربامازيبين وفينيتوين</li><li style="direction: rtl;">الأدوية العشبية التي تحتوي على نبتة سانت جون (هايبريكوم بيرفوراتوم)</li></ul><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">سيخبرك طبيبك إذا كان بإمكانك تناول إدروناكس مع الأدوية الأخرى أم لا. يرجى إبلاغ طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أي أدوية أخرى، بما في ذلك الأدوية التي يتم الحصول عليها دون وصفة طبية والأدوية العشبية وأيضًا الفيتامينات والمعادن.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>إدروناكس مع الطعام والشراب</strong></p><p style="direction: rtl;">يمكن تناول إدروناكس مع الطعام أو بدونه.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>الحمل والرضاعة الطبيعية</strong></p><p style="direction: rtl;">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ ربما تكونين حاملًا أو تخططين للإنجاب، فاستشيري طبيبكِ أو الصيدلي قبل تناول هذا الدواء.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>الحمل</strong></p><p style="direction: rtl;">لا توجد تجارب كافية حول استخدام إدروناكس مع السيدات الحوامل. لا تتناولي إدروناكس إذا كنتِ حاملًا، إلا إذا كان طبيبكِ يرى أن ذلك ضروري للغاية بعد أن يجري دراسة دقيقة للمخاطر/الفوائد الإكلينيكية. أخبري طبيبكِ على الفور إذا كنتِ حاملًا أو تخططين للحمل.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>الرضاعة الطبيعية</strong></p><p style="direction: rtl;">يُفرز إدروناكس في لبن الثدي بكميات صغيرة. وهناك خطر بوجود آثار محتملة على الطفل. لذلك، ينبغي عليكِ مناقشة الأمر مع طبيبكِ، وسوف يقرر إذا ما كان عليكِ إيقاف الرضاعة الطبيعية أو إيقاف العلاج بإدروناكس.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>القيادة واستخدام الآلات</strong></p><p style="direction: rtl;">يوصى بتوخي الحذر عند القيادة أو استخدام الآلات.</p><p style="direction: rtl;">ينبغي عليك عدم القيادة أو تشغيل الآلات إلى أن تتأكد من عدم تأثرك بإدروناكس (كأن تشعر بالنعاس) وأن القيام بذلك آمن بالنسبة لك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">احرص دومًا على تناول<strong> </strong>هذا الدواء تمامًا كما أخبرك طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا مما يجب عليك فعله.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بها للبالغين هي 8 مجم في اليوم (قرص واحد 4 مجم مرتين في اليوم). استنادًا إلى كيفية استجابتك للدواء، قد يخبرك طبيبك بعد مرور 3 إلى 4 أسابيع بأن تتناول ما يصل إلى 10 مجم في اليوم إذا لزم الأمر. ينبغي ألا يتجاوز الحد الأقصى للجرعة يومية 12 مجم.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في المرضى الذين يعانون من ضعف في وظائف الكلى أو الكبد، جرعة البدء هي 4 مجم في اليوم. يمكن زيادة هذه الجرعة حسب الاستجابة الفردية.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يوصى باستخدام أقراص إدروناكس 4 مجم مع المرضى المسنين.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي عدم استخدام إدروناكس مع الأطفال والمراهقين الأصغر من 18 عامًا.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">ينبغي تناول الأقراص على جرعتين منفصلتين، جرعة في الصباح وجرعة في المساء. ينبغي عليك ابتلاع القرص مع كوب من الماء. لا تقم بمضغ القرص.</p><p style="direction: rtl;">لمساعدتك على تذكر تناول إدروناكس، قد تجد أنه من الأسهل تناول الأقراص في نفس الوقت من كل يوم.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">كما هو الحال مع عقاقير أخرى، لن يقوم إدروناكس بتخفيف الأعراض التي تعاني منها على الفور. من المفترض أن تبدأ في الشعور بالتحسن في غضون بضعة أسابيع.</p><p style="direction: rtl;">من المهم أن تستمر في تناول الأقراص، حتى عند شعورك بالتحسن إلى أن ينصحك طبيبك بإيقاف العلاج. يرجى التحلي بالصبر، فقد يُمكن للأعراض التي تعاني منها أن تعود للظهور إذا توقفت عن تناول الأقراص في وقت أبكر من اللازم.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>إذا تناولت جرعة من إدروناكس أكبر مما ينبغي</strong></p><p style="direction: rtl;">ينبغي عليك ألا تتناول أبدًا أقراصًا أكثر مما أوصى بها طبيبك. إذا تناولت أقراصًا أكثر من اللازم، فاتصل بطبيبك أو بالمستشفى المحلي على الفور. إذا تناولت جرعة من إدروناكس أكبر مما ينبغي، فقد تصاب بأعراض تناول الجرعة المفرطة بما في ذلك ضغط الدم المنخفض والقلق وارتفاع ضغط الدم.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>إذا نسيت تناول إدروناكس</strong></p><p style="direction: rtl;">إذا نسيت تناول إدروناكس، فتناول جرعتك التالية في الوقت المعتاد. لا تتناول جرعة مضاعفة لتعويض القرص الذي نسيت تناوله.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>إذا توقفت عن تناول إدروناكس</strong></p><p style="direction: rtl;">ينبغي عليك عدم إيقاف تناول دوائك دون التحدث إلى طبيبك، حيث إن الأعراض التي تعاني منها قد تعود للظهور.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">كانت هناك بعض البلاغات عن ظهور أعراض لسحب الدواء، بما في ذلك الصداع والدوار والعصبية والغثيان (الشعور بالرغبة في التقيؤ)، عندما أوقف المرضى العلاج بإدروناكس.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">إذا كان لديك المزيد من الأسئلة بشأن استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يتسبب هذا الدواء في حدوث آثار جانبية، ولكنها لا تصيب الجميع. معظم الآثار الجانبية الناتجة عن إدروناكس خفيفة وعادة ما تختفي بعد الأسابيع القليلة الأولى من العلاج.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">إذا أصبح أي من الآثار الجانبية الواردة أدناه خطيرًا، أو إذا لاحظت أي آثار جانبية غير مدرجة في هذه النشرة، يُرجى إبلاغ طبيبك أو الصيدلي.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>الآثار الجانبية الشائعة جدًا</strong> (تصيب أكثر من مريض واحد من بين كل 10 مرضى)</p><ul><li style="direction: rtl;">صعوبة النوم (الأرق)</li><li style="direction: rtl;">الدوار</li><li style="direction: rtl;">جفاف الفم</li><li style="direction: rtl;">الإمساك</li><li style="direction: rtl;">الغثيان (الشعور بالرغبة في التقيؤ)</li><li style="direction: rtl;">العرق</li></ul><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>الآثار الجانبية الشائعة</strong> (تصيب أقل من مريض واحد من بين كل 10 مرضى)</p><ul><li style="direction: rtl;">الصداع</li><li style="direction: rtl;">نقص أو فقدان الشهية</li><li style="direction: rtl;">التهيج، القلق</li><li style="direction: rtl;">التنميل (الشكشكة والوخز)، عدم القدرة على الجلوس أو الوقوف بثبات، تغير في حاسة التذوق</li><li style="direction: rtl;">&nbsp;نقص التركيز البصري</li><li style="direction: rtl;">زيادة معدل ضربات القلب، الخفقان (قوة ضربات القلب)</li><li style="direction: rtl;">توسع الأوعية الدموية، انخفاض ضغط الدم عند الوقوف، ارتفاع ضغط الدم</li><li style="direction: rtl;">القيء</li><li style="direction: rtl;">الطفح الجلدي</li><li style="direction: rtl;">الشعور بعدم إفراغ المثانة بالكامل أو إفراغها ببطء، عدوى المسالك البولية، الشعور بألم عند التبول، عدم القدرة على إفراغ المثانة بالكامل</li><li style="direction: rtl;">خلل الانتصاب الوظيفي (ضعف جنسي)، ألم عند القذف أو تأخر القذف</li><li style="direction: rtl;">القشعريرة</li></ul><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>الآثار الجانبية غير الشائعة</strong> (تصيب ما يتراوح بين مريض واحد و10 مرضى من بين كل 1000 مريض)</p><ul><li style="direction: rtl;">توسع الحدقتين</li><li style="direction: rtl;">إحساس بالدوار</li></ul><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>الآثار الجانبية النادرة</strong> (تصيب ما يتراوح بين مريض واحد و10 مرضى من بين كل 10000 مريض)</p><ul><li style="direction: rtl;">الزرق (حالة تؤدي إلى زيادة الضغط داخل العين)</li></ul><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>بعد تسويق ريبوكسيتين، تم الإبلاغ عن الآثار الجانبية التالية:</strong></p><ul><li style="direction: rtl;">نقص صوديوم الدم (مستويات منخفضة للغاية للصوديوم في الدم)</li><li style="direction: rtl;">السلوكيات العدوانية، الهلاوس</li><li style="direction: rtl;">الأفكار الانتحارية، السلوكيات الانتحارية</li></ul><p style="direction: rtl;">تم الإبلاغ عن حالات من الأفكار الانتحارية والسلوكيات الانتحارية أثناء العلاج بريبوكسيتين أو في الفترات التي أعقبت إيقاف العلاج مباشرة (انظر القسم 2 &quot;تحذيرات واحتياطات&quot;)</p><ul><li style="direction: rtl;">برودة الأطراف، ظاهرة رينو (ضعف الدورة الدموية في الأطراف، عادة في أصابع اليدين والقدمين ولكن يمكن أن يؤثر أيضًا على الأنف والأذنين، ويصبح الجلد شاحبًا وباردًا وخدرًا)</li><li style="direction: rtl;">التهاب الجلد الناتج من حساسية</li><li style="direction: rtl;">ألم الخصيتين</li><li style="direction: rtl;">التهيج</li><li style="direction: rtl;">زيادة الضغط داخل العين</li></ul><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p style="direction: rtl;">إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي. يشمل هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول السلامة فيما يتعلق بهذا الدواء</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p style="direction: rtl;"><strong>&nbsp;</strong></p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية</p><table border="0" cellspacing="0" cellpadding="0" style="direction:rtl"><tbody><tr><td style="vertical-align:top"><p>المركز الوطني للتيقظ والسلامة الدوائية (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp; فاكس: +96611205 7662</p><p>&middot;&nbsp;&nbsp;&nbsp; اتصل بالمركز الوطني للتيقظ والسلامة الدوائية على الرقم: 00966112038222، تحويلة: 2317-2356-2340</p><p>&middot;&nbsp;&nbsp;&nbsp; الهاتف المجاني: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table><p style="direction: rtl;"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li style="direction: rtl;">يخزن إدروناكس في درجة حرارة أقل من 30 درجة مئوية.</li><li style="direction: rtl;">يحفظ بعيدًا عن متناول ومرأى الأطفال.</li></ul><ul><li style="direction: rtl;">مدة الصلاحية: 24 شهرًا</li></ul><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">لا تتخلص من الأدوية عبر مياه الصرف أو في القمامة المنزلية. اسأل الصيدلي الخاص بك عن كيفية التخلص من الأدوية التي لم تعد هناك حاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">المادة الفعالة هي ريبوكسيتين.</p><ul><li style="direction: rtl;">يحتوي كل قرص على 4 مجم من ريبوكسيتين</li></ul><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">المكونات الأخرى هي:</p><ul><li style="direction: rtl;">سليولوز بلوري مكروي، وهيدروجين فوسفات الكالسيوم ثنائي الهيدرات، وكروسبوفيدون، وسيليكا غروانية مميهة، وستيارات المغنيسيوم.</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            أقراص إدروناكس هي أقراص بيضاء دائرية محدبة بها حز يساعد على كسرها. تحمل الأقراص العلامة "P" إلى يسار حز الكسر والعلامة "U" إلى يمينه. يحمل الجانب المقابل لحز الكسر العلامة "7671". يمكن تقسيم القرص إلى جرعتين متساويتين.

إدروناكس متاح في عبوات بها شرائط بليستر تحتوي على 10 أو 20 أو 50 أو 60 أو 100 أو 120 أو 180 قرصًا، وقوارير زجاجية تحتوي على 60 قرصًا، وعبوات متعددة بها 3×60 أو 5×60 أو 10×60 قرصًا في شرائط بليستر، و3×60 أو 5×60 أو 10×60 قرصًا في قوارير زجاجية. 

قد لا يتم طرح جميع أحجام العبوات في الأسواق.

        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;"><strong>مالك تصريح التسويق:</strong></p><p style="direction: rtl;">PFIZER ITALIA S.R.L &ndash; VIA ISONZO, 71 &ndash; 04100 Latina</p><p style="direction: rtl;"><strong>&nbsp;</strong></p><p style="direction: rtl;"><strong>الجهة المصنعة:</strong></p><p style="direction: rtl;">Pfizer Italia S.r.l. - 63100 Localita Marino Del Tronto - Ascoli Piceno, Italy، إيطاليا</p><p style="direction: rtl;">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            	تمت المراجعة الأخيرة لهذه النشرة في يونيو/حزيران 2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EDRONAX 4 mg Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One tablet contains 4 mg of reboxetine 
For full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet
White, round, convex tablet with a breakline on one side. A ‘P’ is marked on the left side of the breakline. A ‘U’ is marked on the right side of the breakline. The side opposite the breakline is marked ‘7671’. The tablet can be divided into equal halves.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reboxetine is indicated for the acute treatment of depressive illness/major depression and for maintaining the clinical improvement in patients initially responding to treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reboxetine is for oral use.</p><p><u>Use in adults</u></p><p>The recommended therapeutic dose is 4&nbsp;mg twice a day (b.i.d.) i.e.8&nbsp;mg/day administered orally. The full therapeutic dose can be given upon starting treatment. After 3-4 weeks, this dose can be increased to 10&nbsp;mg/day in case of incomplete clinical response. The maximum daily dose should not exceed 12&nbsp;mg/day. The minimum effective dose has not yet been established.</p><p>&nbsp;</p><p><u>Use in the elderly</u></p><p>Elderly patients have been studied in clinical trials at doses of 2&nbsp;mg b.i.d. However, safety and efficacy have not been evaluated in placebo-controlled conditions. Therefore, as for other antidepressants that have not been studied in placebo-controlled conditions, reboxetine cannot be recommended.</p><p>&nbsp;</p><p><u>Use in children and adolescents under the age of 18 years</u></p><p>Reboxetine should not be used in the treatment of children and adolescents under the age of 18&nbsp;years (see section 4.4).</p><p>&nbsp;</p><p><u>Use in patients with renal or hepatic insufficiency</u></p><p>The starting dose in patients with renal or hepatic insufficiency should be 2&nbsp;mg b.i.d which can be increased based on patient tolerance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Known hypersensitivity to reboxetine or any of the components of the product.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Use in children and adolescents under 18 years of age</p><p>Reboxetine should not be used in the treatment of children and adolescents under the age of 18&nbsp;years. Suicide-related behaviours (suicide attempt and suicidal thoughts), and hostility (predominantly aggression, oppositional behaviour and anger) were more frequently observed in clinical trials among children and adolescents treated with antidepressants compared to those treated with placebo. If, based on clinical need, a decision to treat is nevertheless taken, the patient should be carefully monitored for the appearance of suicidal symptoms. In addition, long-term safety data in children and adolescents concerning growth, maturation and cognitive and behavioural development are lacking.</p><p>&nbsp;</p><p>As reboxetine has not been tested in patients with convulsive disorders in clinical studies and since rare cases of seizures have been reported in clinical studies, it should be given under close supervision to subjects with a history of convulsive disorders and it must be discontinued if the patient develops seizures.</p><p>&nbsp;</p><p>Concomitant use of MAO-inhibitors (including linezolid (an antibiotic which is a reversible non‑selective MAOI) and methylene blue) and reboxetine should be avoided in view of the potential risk (tyramine-like effect) based on their mechanisms of action.</p><p>&nbsp;</p><p>Concomitant use of reboxetine with other antidepressants (tricyclics, MAO inhibitors, SSRIs and lithium) has not been evaluated during clinical trials.</p><p>&nbsp;</p><p>As with all antidepressants, switches to mania/hypomania have occurred during the clinical studies. Close supervision of bipolar patients is, therefore, recommended.</p><p>&nbsp;</p><p><strong>Suicide/suicidal thoughts or clinical worsening:</strong><br />Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide‑related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.</p><p><s>&nbsp;</s></p><p>Patients with a history of suicide‑related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta‑analysis of placebo‑controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25&nbsp;years old.</p><p>&nbsp;</p><p>Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.</p><p>&nbsp;</p><p>Clinical experience with reboxetine in patients affected by serious concomitant systemic illnesses is limited. Close supervision should be applied in patients with current evidence of urinary retention, prostatic hypertrophy, glaucoma and<strong> </strong>history of cardiac disease.</p><p>&nbsp;</p><p>At doses higher than the maximum recommended, orthostatic hypotension has been observed with greater frequency than that observed at recommended doses. Particular attention should be paid when administering reboxetine with other drugs known to lower blood pressure.</p><p>&nbsp;</p><p>Clinical experience with reboxetine in the long-term treatment of elderly patients is, at present, limited. In this population, lowering of mean potassium levels was found starting from week&nbsp;14; the magnitude of this reduction did not exceed 0.8&nbsp;mmol/litre and potassium levels never dropped below normal limits.</p><p>&nbsp;</p><p>Mydriasis has been reported in association with reboxetine; therefore, caution should be used when prescribing reboxetine to patients with increased intraocular pressure or those at risk of acute narrow-angle glaucoma.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>In vitro</em> metabolism studies indicate that reboxetine is primarily metabolised by the CYP3A4 isozyme of cytochrome P450; reboxetine is not metabolized by CYP2D6. Therefore potent inhibitors of CYP3A4 (ketoconazole, nefazodone, erythromycin and fluvoxamine), would be expected to increase plasma concentrations of reboxetine. In a study in healthy volunteers, ketoconazole, a potent inhibitor of CYP3A4, was found to increase plasma concentrations of the reboxetine enantiomers by approximately 50%. Because of reboxetine&rsquo;s narrow therapeutic margin, inhibition of elimination is a major concern. Reboxetine, therefore should not be given together with drugs known to inhibit CYP3A4 such as azole antifungal agents, macrolide antibiotics such as erythromycin, or fluvoxamine.</p><p>&nbsp;</p><p>Low reboxetine serum levels have been reported with the concurrent administration of CYP3A4 inducers such as phenobarbital and carbamazepine. Examples of other CYP3A4 inducers that may reduce the serum levels of reboxetine include but are not limited to phenytoin, rifampicin and St John&acute;s Wort.</p><p>&nbsp;</p><p><em>In vitro</em> studies have shown that reboxetine does not inhibit the activity of the following P450 isoenzymes: CYP1A2, CYP2C9, CYP2C19 and CYP2E1. Pharmacokinetic interactions would not be expected with compounds metabolised by these enzymes. At concentrations which exceed those in clinical use, reboxetine inhibits CYP2D6 and CYP3A4, however, the results of <em>in vivo</em> studies suggest that interactions with other drugs metabolised by these enzymes are unlikely.</p><p>&nbsp;</p><p>No significant reciprocal pharmacokinetic interaction has been found between reboxetine and lorazepam. During their co-administration in healthy volunteers, mild to moderate drowsiness and short lasting orthostatic acceleration of heart rate have been observed.</p><p>&nbsp;</p><p>Reboxetine does not appear to potentiate the effect of alcohol on cognitive functions in healthy volunteers.</p><p>&nbsp;</p><p>Concomitant use of MAO-inhibitors (including linezolid (an antibiotic which is a reversible non‑selective MAOI) and methylene blue) and reboxetine should be avoided in view of the potential risk (tyramine-like effect) based on their mechanisms of action.</p><p>Concomitant use of reboxetine with other antidepressants (tricyclics, MAO inhibitors, SSRIs and lithium) has not been evaluated during clinical trials.</p><p>&nbsp;</p><p>Concomitant use of ergot derivatives and reboxetine might result in increased blood pressure.</p><p>&nbsp;</p><p>Food intake delayed the absorption of reboxetine, but did not significantly influence the extent of absorption.</p><p>&nbsp;</p><p>Although data are not available from clinical studies, the possibility of hypokalaemia with concomitant use of potassium losing diuretics should be considered.</p><p>&nbsp;</p><p>In an in vivo multiple-dose study performed in healthy volunteers, no clinically significant interaction between fluoxetine and reboxetine was observed. In patients, a different effect and safety profile upon combination of reboxetine and fluoxetine cannot be excluded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>No clinical trial data on exposure to reboxetine during pregnancy are available. However, postmarketing safety data on a very limited number of exposed pregnancies indicate no adverse effects of reboxetine on pregnancy or on the health of the foetus/newborn child.</p><p>Animal studies in general do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development or parturition. Some impairment of growth and development has been noted in rat neonates (see section 5.3).</p><p>Reboxetine should only be used in pregnancy if the potential benefits of treatment to the mother outweigh the possible risks to the developing foetus.</p><p><strong>&nbsp;</strong></p><p><strong>Lactation</strong></p><p>Reboxetine is known to be excreted in breast milk. The level of active substance transferred in breast milk is anticipated to be very low, however there is insufficient information to exclude a risk to the nursing infant. The use of reboxetine during breastfeeding can be considered if the potential benefits outweigh the risk for the child.</p><p>&nbsp;</p><p><strong>Fertility</strong></p><p>There is no clinical trial data on fertility. However, in animal studies no effect on fertility parameters was observed (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Although reboxetine has been shown to have negligible effect on psychomotor performance in healthy volunteers, any psychoactive drug can impair judgement or skills. Patients should be cautioned about driving or operating hazardous machinery until reasonably certain that their performance has not been affected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Over 2100 patients received reboxetine in clinical studies, approximately 250 of which received reboxetine for at least<strong> </strong>1 year.</p><p>&nbsp;</p><p>The information provided in <em>Table 1</em> below is a summary of adverse events observed in patients treated with reboxetine in placebo-controlled clinical studies of 8 weeks duration or less. In addition, the table also includes adverse events observed from postmarketing experience (frequency not known).</p><p>&nbsp;</p><p><strong><u>Table 1: Adverse Events</u></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:528px"><tbody><tr><td style="vertical-align:top"><p><strong>Very Common (&ge;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common<br />&nbsp;</strong><strong>(&ge;1/100 to&nbsp; &lt;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge;1/1000 to &lt;1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare (&ge;1/10000 to &lt;1/1000)</strong></p></td><td style="vertical-align:top"><p><strong>Frequency not Known</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Metabolism and nutrition disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyponatraemia</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Psychiatric disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>Agitation*, Anxiety*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Aggressive behaviour, Hallucination, Suicidal Ideation/behaviour**</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Nervous system disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Dizziness,</p></td><td style="vertical-align:top"><p>Headache, Paraesthesia*, Akathisia, Dysguesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Eye disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Accommodation disorder</p></td><td style="vertical-align:top"><p>Mydriasis*</p></td><td style="vertical-align:top"><p>Glaucoma*</p></td><td style="vertical-align:top"><p>Intraocular pressure increased</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Ear and labyrinth disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Cardiac disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tachycardia, Palpitations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Vascular disorders</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Vasodilatation, Hypotension, Hypertension*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Peripheral coldness, Raynaud`s phenomenon</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Dry mouth, Constipation, Nausea*</p></td><td style="vertical-align:top"><p>Vomiting*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Hyperhidrosis</p></td><td style="vertical-align:top"><p>Rash*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Allergic dermatitis</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Renal and urinary disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sensation of incomplete bladder emptying, Urinary tract infection, Dysuria, Urinary retention</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Reproductive system and breast disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Erectile dysfunction, Ejaculatory pain, Ejaculatory delay&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Testicular pain</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Chills</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Irritability</p></td></tr></tbody></table><p><em>&nbsp;* these adverse events also occurred in postmarketing experience</em></p><p>** Cases of suicidal ideation and suicidal behaviours have been reported during reboxetine therapy or early after treatment discontinuation (see section 4.4).</p><p>&nbsp;</p><p>In placebo-controlled studies of 8 weeks duration or less, adverse events were reported in approximately 80% of reboxetine-treated patients and in approximately 70% of placebo-treated patients. Discontinuation rates for adverse events were approximately 9% and 5% for reboxetine-and placebo-treated patients, respectively.</p><p>&nbsp;</p><p>As for long-term tolerability, 143 reboxetine-treated and 140 placebo-treated adult patients participated in a long term placebo controlled study. Adverse events newly emerged on long term treatment in 28% of the reboxetine treated patients and 23% of the placebo-treated patients and caused discontinuation in 4% and 1% of the cases respectively. There was a similar risk of the development of individual events with reboxetine and placebo. In the long term studies, no individual events were seen which have not been seen on short term treatment.</p><p>&nbsp;</p><p>In short-term controlled studies of patients with depression, no clinically significant between-gender differences were noted in the frequency of treatment emergent symptoms, with the exception of urologic events (such as the sensation of incomplete bladder emptying, dysuria and urinary frequency), which were reported in a higher percentage of reboxetine-treated male patients (31.4% [143/456]) than reboxetine-treated female patients (7.0% [59/847]). In contrast, the frequency of urologic-related events was similar among male (5.0% [15/302]) and female (8.4% [37/440]) placebo-treated patients.</p><p>&nbsp;</p><p>In the elderly population, frequency of total adverse events, as well as of individual events, was no<strong> </strong>higher than that reported above.</p><p>&nbsp;</p><p>In pre-marketing clinical studies, signs and symptoms newly reported following discontinuation occurred in approximately (5%) of the reboxetine treated patients and approximately (4%) of placebo-treated patients. In post-marketing experience, there have been a few spontaneous reports of withdrawal symptoms including headache, dizziness, nervousness and nausea; however, no consistent pattern of events on cessation of treatment with reboxetine was evident in these reports.</p><p>&nbsp;</p><p>In those short-term studies in depression where heart rate was assessed with ECG, reboxetine was associated with mean increases in heart rate, compared to placebo, of 6 to 12 beats per minute.</p><p>&nbsp;</p><p>In all short-term controlled studies in depression, the mean change in pulse (in beats per minute) for reboxetine-treated patients was 3.0, 6.4 and 2.9 in the standing, sitting and supine positions respectively, compared with 0, 0, and &ndash;0.5 for placebo-treated patients in the corresponding positions. In these same studies, 0.8% of reboxetine-treated patients discontinued the drug because of tachycardia compared with 0.1% of placebo-treated patients.</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after marketing authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions according to their local country requirements.</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><ul><li>Saudi Arabia</li></ul><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance and Drug Safety Centre ( NPC )</p><ul><li>Fax: +966 11 205 7662</li></ul><ul><li>Call NPC at 00966 11 2038222, Exts: 2317-2356-2340</li><li>SFDA Call Center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/</li></ul><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The acute toxicity studies carried out in animals indicate a very low toxicity, with a wide safety margin with respect to the pharmacologically active doses. Clinical signs and cause of death were related to CNS stimulation (mainly convulsive symptoms).</p><p>&nbsp;</p><p>In a few cases doses higher than those recommended were administered to patients (12&nbsp;mg to 20&nbsp;mg/day) for a period ranging from a few days to some weeks during clinical studies: newly reported complaints include postural hypotension, anxiety and hypertension<em>.</em> Elderly might be particularly vulnerable to overdose.</p><p>&nbsp;</p><p>In premarketing clinical studies, there were 5 reports of reboxetine overdose alone or in combination with other pharmacologic agents. The amount of reboxetine ingested was 52&nbsp;mg as the sole agent by 1 patient and 20&nbsp;mg in combination with other agents by another patient. The remaining 3 patients ingested unknown quantities of reboxetine. All 5 patients recovered fully. There were no reports of ECG abnormalities, coma, or convulsions following overdose with reboxetine alone.</p><p>&nbsp;</p><p>In postmarketing experience, there have been few reports of overdose in patients taking reboxetine alone; none of these have proved fatal. Non-fatal overdoses in patients have been reported for patients taking up to 240&nbsp;mg of reboxetine. One fatal overdose was reported in a patient who ingested reboxetine in combination with amitriptyline (doses unknown).</p><p>&nbsp;</p><p>In case of overdose, monitoring of cardiac function and vital signs is recommended. General symptomatic supportive and/or emetic measures might be required.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other Antidepressants</p><p>ATC code: NO6A X18</p><p>&nbsp;</p><p>Reboxetine is a highly selective and potent inhibitor of noradrenaline reuptake. It has only a weak effect on the 5-HT reuptake and does not affect the uptake of dopamine.</p><p>&nbsp;</p><p>Noradrenaline reuptake inhibition and the consequent increase of noradrenaline availability in the synaptic cleft and modification of noradrenergic transmission, reportedly is among the most relevant mechanisms of action of known antidepressant drugs.</p><p>&nbsp;</p><p><em>In vitro</em>, studies have shown that reboxetine has no significant affinity for adrenergic (a<sub>1</sub>, a<sub>2</sub>, b) and muscarinic receptors; antagonism of such receptors has been described to be associated with cardiovascular, anticholinergic and sedative side effects of other antidepressant drugs. Reboxetine is devoid of <em>in vitro</em> binding affinity for either a<sub>1</sub> or a<sub>2</sub> adrenoceptors, however,<strong> </strong>a functional interference with a-adrenoceptors at high doses <em>in vivo</em> cannot be excluded.</p><p>&nbsp;</p><p>In a post hoc stratified analysis of data from 11 placebo-controlled trials involving 2400 patients, there was no statistical difference in response rates on the primary endpoint (HAMD 21 item scale) for reboxetine versus placebo patients with mild to moderate severity of depression. Efficacy was only clearly demonstrated in patients with severe or very severe depression. From these trials there are limited efficacy data available in the use of reboxetine in patients with mild to moderate severity of depression.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After oral administration of a single 4&nbsp;mg reboxetine dose to healthy volunteers, peak levels of about 130&nbsp;ng/ml are achieved within 2&nbsp;h post-dosing. Data indicate that absolute bioavailability is at least 60%.</p><p>&nbsp;</p><p>Reboxetine plasma levels decreased monoexponentially with a half-life of about 13&nbsp;h. Steady-state conditions are observed within 5 days. Linearity of the pharmacokinetics was shown in the range of single oral doses in the clinically recommended dose-ranges.</p><p>&nbsp;</p><p>The drug appears to be distributed into total body water. Reboxetine is 97 % bound to human plasma proteins in young and 92% in elderly<strong><u> </u></strong>(with affinity markedly higher for a<sub>1</sub> acid glycoprotein than albumin), with no significant dependence of the concentration of drug.</p><p>&nbsp;</p><p>Reboxetine is predominantly metabolised <em>in vitro</em> via cytochrome P4503A (CYP3A4). <em>In vitro</em> studies have shown that reboxetine does not inhibit the activity of the following isozymes of cytochrome P450: CYP1A2, CYP2C9, CYP2C19, and CYP2E1. Reboxetine inhibits both CYP2D6 and CYP3A4 with low binding affinities, but has shown no effect on the <em>in vivo</em> clearance of drugs metabolized by these enzymes. Reboxetine should be co-prescribed with caution with potent inhibitors of CYP3A4.</p><p>&nbsp;</p><p>The amount of radioactivity excreted in urine accounts for 78 % of the dose. Even though unchanged drug is predominant in the systemic circulation (70% of total radioactivity, in terms of AUC), only 10% of the dose is excreted as unchanged drug in urine. These findings suggest that biotransformation rules the overall elimination of reboxetine and that metabolites excretion is limited by their formation. The main metabolic pathways identified are 2-O-dealkylation, hydroxylation of the ethoxyphenoxy ring and oxidation of the morpholine ring, followed by partial or complete glucuro- or sulpho-conjugation.</p><p>&nbsp;</p><p>The drug is available as a racemic mixture (with both enantiomers being active in the experimental models): no chiral inversion, nor reciprocal pharmacokinetic interferences between enantiomers have been observed. Plasma levels of the more potent SS enantiomer are about two times lower and urinary excretion two times higher than those of the enantiomeric counterpart. No significant differences were observed in the terminal half-lives of the two enantiomers.</p><p>&nbsp;</p><p>Increases in systemic exposure and half-life of approximately two-fold are observed in patients with renal insufficiency and hepatic insufficiency. Similar or somewhat greater (3-fold) increases in systemic exposure also occur in elderly patients relative to young healthy volunteers.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reboxetine did not induce gene mutations in bacterial or mammalian cells <em>in vitro</em> but induced chromosomal aberrations in human lymphocytes <em>in vitro</em>. Reboxetine did not cause DNA damage in yeast cells or rat hepatocytes <em>in vitro</em>. Reboxetine did not cause chromosomal damage in an <em>in vivo</em> mouse micronucleus test, and did not increase tumor incidence in carcinogenecity studies in mice and rats.</p><p>&nbsp;</p><p>Haemosiderosis was reported in toxicity studies in rats only.</p><p>&nbsp;</p><p>Studies in animals have not demonstrated any teratogenic effect or any effect of the compound on global reproductive performance. In fertility studies in rats, reboxetine did not alter mating behavior, fertility or general reproductive performance at oral doses up to 90&nbsp;mg/kg/day.</p><p>&nbsp;</p><p>Dosages that produced plasma concentrations within the therapeutic range for humans induced an impairment of growth and development and long term behavioural changes in offspring of rats.</p><p>&nbsp;</p><p>In rats reboxetine is excreted in milk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cellulose microcrystalline</p><p>Calcium hydrogen phosphate dihydrate</p><p>Crospovidone</p><p>Silica, colloidal hydrated</p><p>Magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months 

Keep out of the sight and reach of children.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30 &deg; C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The tablets are contained either in amber glass, type III, bottle, closed with an aluminium pilfer-proof screw cap equipped with a polyethylene undercap or in aluminium-PVDC / PVC-PVDC opaque blisters.</p><p>Each pack contains:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>10, 20, 50, 60, 100, 120, and 180 tablets in blisters;</p><p>&nbsp;and 60 tablets in glass bottles.</p><p>&nbsp;</p><p>Multipacks of 3x60, 5x60 and 10x60 tablets in blisters; and 3x60, 5x60 and 10x60 tablets in glass bottles.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER:
PFIZER ITALIA S.R.L – VIA ISONZO, 71 – 04100 LATINA

MANUFACTURER:
PFIZER ITALIA S.R.L, LOCALITÀ MARINO DEL TRONTO - 63100 ASCOLI PICENO

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>